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Four decades ago, specialized chemotherapy regimens turned osteosarcoma, once considered a uniformly fatal disease, into a
disease in which a majority of patients survive. Though signiﬁcant survival gains were made from the 1960s to the 1980s, further
outcome improvements appear to have plateaued. This study aims to comprehensively review all signiﬁcant, published data
regarding osteosarcoma and outcome in the modern medical era in order to gauge treatment progress. Our results indicate that
published survival improved dramatically from 1960s to 1980s and then leveled, or in some measures decreased. Recurrence rates
decreased in the 1970s and then leveled. In contrast, published limb salvage rates have increased signiﬁcantly every recent decade
until the present. Though signiﬁcant gains have been made in the past, no improvement in published osteosarcoma survival
has been seen since 1980, highlighting the importance of a new strategy in the systemic management of this still very lethal
condition.
1.Introduction
Osteosarcoma was once considered such a fatal condition
that early studies measured outcome in terms of “months to
metastasis” rather than actual survival. Shortly after the turn
ofthelastcentury,Coventrymeasuredosteosarcomasurvival
at 5% [1]. In the 1950s, neither surgery, nor radiation, nor
rudimentary chemotherapy regimens signiﬁcantly impacted
survival, with the largest study of the decade citing a 22% 5-
year survival [1]. With the advent of higher dose, multiagent
chemotherapy regimens, 5-year survival steadily increased to
as high as 81.6% in the 1970s [2].
However, casual inspection of published data indicates
that since the 1970s, survival and perhaps other outcome
measures have yet to further improve. As surgical techniques
and implants have evolved, chemotherapeutic agents used
today seem to be wholly similar to those used thirty years
ago.
A meta-analysis of the world’s data regarding osteosar-
coma and outcomes would help us accurately gauge our
current state of treatment and not just speculate on
improvements or stasis based on isolated recent studies and
anecdotal evidence. Several studies have attempted similar
meta-analyses; however, their scales were much smaller (the
largest of which contained 142 series) and their scopes were
narrower (focusing only on speciﬁc therapies) than our
intended breadth [3–5]. The purpose of our study is to thor-
oughly inspect the expansive literature regarding prognosis
of osteosarcoma since the inception of journal publication,
in order to analyze the treatment trends across the globe in
regards to time. Thus, we aim to determine treatment
progress, as well as the current state of aﬀairs, so that we may
in turn accurately gauge our progress and appropriately di-
rect our eﬀorts.
2.MaterialsandMethods
A comprehensive and complete MEDLINE search was per-
formed, using only the search terms “osteosarcoma” and
“survival.” Articles not written or translated into English,2 Sarcoma
animal or in vitro studies, and articles not accessible through
the University of Southern California Norris Medical Library
were excluded. All articles describing outcome data were in-
cluded, including clinical trials, case series, databases, letters,
and reviews. General case series with less than 20 total
patients were excluded. All studies including nonclassic or
lower grade osteosarcoma variants as well as secondary oste-
osarcoma or recurrent osteosarcoma were excluded, as were
head and neck cases. Pelvic and axial tumors were included.
Studies that measured survival in terms of odd years (e.g.,
7-year survival) and, for studies published after 1980, those
series which measured outcomes in less than 5-year terms
were also excluded. Metastatic series were included, however,
they were left apart from the general studies and analyzed
separately.
Both overall survival (OS) and disease-free survival
( D F S )o f5y e a r so rm o r ew e r er e c o r d e df r o me a c hs t u d y ,
focusing on 5- and 10-year survival numbers when possible.
Local recurrence and limb salvage rates were also measured,
if data was given. Each study was then assigned to speciﬁc
time intervals (decades), which were determined by the
described study period of each series. If a series spanned two
decades, it was placed in the decade in which a majority of
the study time occurred, rounding to the more recent decade
if the division was equal. If a series spanned more than two
decades, it was placed in a separate table for direct review
(Table 1), and not included in the decade-to-decade analysis.
If the article did not mention the time period, the study was
placed into the decade preceding that of publication. If a
study was divided according to decade or time period, each
arm was placed into its separate decade category accordingly.
Of 3,948 initial series found in the search for “osteosar-
coma” and “survival,” 3,684 did not meet the study inclusion
criteria, leaving a total of 264 series in the study. Data
from these series were then combined in weighted fashion
(according to the number of patients in each study) in order
to obtain mean values for each respective outcome measure.
Nonmetastatic cases were evaluated in terms of survival (OS
(5,10year)andDFS(3,5,and10year))recurrence,andlimb
salvage rates, and analyzed according to decade. Articles that
recorded speciﬁc subtypes (metastatic cases, pelvis, and limb
salvage) were also analyzed separately according to decade
with regard to 5-year OS. The data from metastatic series
were not included in the general survival, limb salvage, and
recurrence data. Along each outcome measure, these means
were then compared according to the t-test for proportions,
set to a 95% conﬁdence interval.
3. Results
3.1. General Survival. Among the series of nonmetastatic,
high-grade osteosarcoma patients, the most commonly mea-
sured statistic, 5-year OS was measured in 47,227 patients
throughout the series. Figure 1 shows the 5-year OS trend
from the beginning of the twentieth century to present day.
Survival remained stable at approximately 20% from the
1910s to the 1960s, with a sudden surge to approximately
60% into the 1980s where it stabilized again. The increase
in 5-year OS from the 1960s to the 1970s (P<0.0001) and
from the 1970s to the 1980s (P<0.0001) was statistically
signiﬁcant;however,whencomparingthe1980stothe2000s,
no further statistically signiﬁcant increase in published 5-
year OS was recorded (P = 0.66). Ten-year OS increased by
37.6% from the 1960s to the 1970s (P<0.0001), but then
showednodiﬀerencewhencomparingthe2000stothe1990s
(P = 0.28) (Figure 2).
Disease-free survival was ﬁrst recorded in the 1950s
studies, starting with 3-year DFS measures. Three-year DFS
increasedsigniﬁcantlyfromthe1950stothe1960s(P = 0.05)
and from the 1960s to the 1970s (P<0.0001), but then failed
to improve after the 1970s (Figure 3). The published 5-year
DFS increased by 8.6% from the 1970s to the 1980s (P<
0.0001) and 2.6% from the 1980s to the 1990s (P = 0.0007),
but then signiﬁcantly decreased by 11.2% from 1990 to 2000
(P<0.0001) (Figure 4). Similarly 10-year DFS remained sta-
ble in the 1970s, 1980s, and 1990s at roughly 60%, only
to statistically decrease to 44% in the 2000s (P<0.0001)
(Figure 5).
3.2. Local Control and Limb Salvage. Recurrence measures
were initially published in the 1970s, and have ﬂuctuated
from decade to decade since (Figure 6). No signiﬁcant
improvement has been seen in published recurrence rates
from the 1980s to the 2000s (P = 0.36).
Limb salvage rates have improved signiﬁcantly from dec-
ade to decade ever since the 1970s, improving by 16.2% from
the 1970s to 1980s (P = 0.01), by 37% from the 1980s to the
1990s(P<0.0001),andby7.3%fromthe1990stothe2000’s
(P<0.0001) (Figure 7).
3.3.SurvivalinSpeciﬁcOsteosarcomaPopulations. Startingin
the 1970’s, cases of metastatic osteosarcoma were analyzed in
separate series. Five-year survival rates in metastatic series
improved from the 1970’s to the 1980’s by 5.7%, though
this change was not statistically signiﬁcant. Interestingly, 5-
year survival rates in this population have decreased every
decade ever since, with no statistical change in survival when
comparing the 2000’s to the 1970’s (P = 0.21) (Figure 8).
Whenlookingspeciﬁcallyatseriesofpelvicosteosarcoma
patients, survival rates have also declined every decade since
their ﬁrst recording in the 1980’s; however these drops were
not statistically signiﬁcant (Figure 9).
In speciﬁcally documented limb salvage series, 5-year OS
rates improved signiﬁcantly from the 1990’s to the 2000’s by
11.1% (P = 0.04) and from 1970’s to the 2000’s by 23.1%
(P<0.0001) (Figure 10).
4. Discussion
Advances in chemotherapy regimens in the seventies lead to
extraordinary increases in survival of osteosarcoma patients
which, combined with improved surgical technology and
technique, also lead to signiﬁcant improvements in limb
salvage. Physicians anecdotally refer to the lack of survival
progress in the latter end of the last century, yet few studies
probe into the extensive world literature. The few that at-
tempt to address this issue narrow their reviews to control-
lable numbers: as few as 8 in one review [5]. Anninga et al.Sarcoma 3
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Figure 1: Osteosarcoma 5-year overall survival.
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Figure 2: Osteosarcoma 10-year overall survival.
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Figure 3: Osteosarcoma 3-year disease-free survival.Sarcoma 7
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Figure 4: Osteosarcoma 5-year disease-free durvival.
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Figure 5: Osteosarcoma 10-year disease-free survival.
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Figure 6: Osteosarcoma recurrence rates.8 Sarcoma
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Figure 7: Osteosarcoma limb salvage rates.
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Figure 8: Metastatic osteosarcoma 5-year overall survival.
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Figure 9: Pelvic osteosarcoma 5-year overall survival.Sarcoma 9
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Figure 10: Osteosarcoma 5-year overall survival among limb salvage cases.
recently published the previously most comprehensive re-
view, but looked at speciﬁc treatment regimens and excluded
other prognostic, observational, and review studies [3]. We
aimed to sort through the extensive osteosarcoma literature
to arrive at basic evidence-based interpretations regarding
the current status of osteosarcoma management, as it relates
to our past. Such information will help us determine the
most appropriate steps to take as an osteosarcoma-treating
community as we progress into the new century.
Despite its expansive scale, our study certainly has im-
portant limitations. Our numbers are based on published
studies, which may not accurately represent outcomes in the
community as a whole. Many successive studies may contain
duplicatepatients,skewingthedatainthisdirection.Accord-
ing to our exclusion criteria, we may have excluded impor-
tant contributing data, especially with the removal of stud-
ies with odd-year survival measures. Nevertheless, the USC
Norris Medical Library is extensively complete, and the ex-
clusion criteria narrow, decreasing the likelihood of missing
signiﬁcant data. Furthermore, our retrieved number of
studies was so high that the addition of this data is very
unlikely to change any calculation. Furthermore, the analysis
of the extensive amount of data could pose limitations. The
homogenous blending of diﬀerent survival curves from het-
erogenous populations could skew outcome results. The in-
corporation of numerous studies with large numbers of
patients helps mitigate this risk for error. Not all of the pre-
dominately survival studies gave data on recurrence or limb
salvagerates.Thesenumberswereweightedaveragedaccord-
ing to decade; however the exact number and subsequent
power of their information is less than that of survival; how-
ever, even with these lower numbers, the numbers were still
high enough to note signiﬁcant diﬀerences. Combining all
osteosarcoma patient populations together may also skew
results,ascertainpatientpopulationsmayhavediﬀerentout-
comes (i.e., axial versus appendicular cases). In order to
addressthislimitation,weanalyzedspeciﬁcpopulationseries
separately in order to show their survival data (Figures 8, 9,
and 10). Combining single center and multicenter studies
also poses a limitation, increasing the associated variables
such as treatment regimens and outcome measures. Again,
theveryhighnumbersretrievedinourstudy(47,227patients
in the 5 year overall survival data) help mitigate these lim-
itations.
Our study conﬁrms suspicions regarding the lack of
statistical improvement in osteosarcoma survival over the
lastthirtyyears.Infact,DFSatthe3-year,5-year,and10-year
marks have shown recent decreases over the last two decades.
Aftersteepimprovementsupuntilthe1970’s,overallsurvival
at the 5 and 10-year marks has simply plateaued with lack of
statistical improvements. Similarly, recurrence rates have
ﬂuctuated in the modern era, without signiﬁcant improve-
ment. This lack of improvement is also true in subset
populationslikepelvicmetastaticcases,withactualdecreases
in survival in both of these populations over the last two
decades, though these decreases did not reach statistical
signiﬁcance. Of note, limb salvage rates as well as survival
rates in limb salvage populations, have continued to climb,
increasing signiﬁcantly since the 1970’s on both accounts.
This progress may indicate improvements in biopsy, respec-
tive techniques, and limb salvage reconstructive methods.
In a time of unprecedented technological growth and
advance, systemic cancer treatment clearly lags behind. This
lagisfurtheraccentuatedbythetremendoussurgeinsurvival
of osteosarcoma until the 1980’s. Our study indicates that
this stagnation is not limited to a single outcome measure,
but across all outcomes ranging from survival to recurrence.
After noting the problem, our next charge is to ﬁnd the
underlying cause. Given the expense of drug development,
trialing, and now even marketing, the relatively low numbers
associated with osteosarcoma, especially in relation to vis-
ceral malignancy, renders the orphan condition less popular
among pharmaceutical companies that have an obligation to
shareholders. Furthermore, the lack of proﬁt from cure of
disease as opposed to prolongation of disease likely lessens
the industry’s quest for a cure. Unfortunately, in the current
system, economic incentives do not always align with patient
wellness incentives. A similar problem was addressed with10 Sarcoma
osteosarcoma in the early 1970’s with the touching story
of Terry Fox, which highlighted the lack of eﬀorts put into
osteosarcoma research and drug development. The patient’s
story, which became a feature ﬁlm, helped spawn an un-
precedented interest and motivation in curing the disease
worldwide. Perhaps eﬀorts to show the public the plights of
the often young patients struck with this disease will lead to a
second surge in interest. Another potential cause of this lack
of progress could be complacency among those who treat
sarcomas. While many oncologists have cited the lack of
progressinthetreatmentofnon-sarcomacancersinthepast,
opponents would cite the survival jump of osteosarcoma as a
sign of cancer ﬁghting progress. The idea that osteosarcoma
isabastionofchemotherapeuticadvancemayhavedecreased
the scientiﬁc sense of urgency in ﬁnding a cure.
Regardless of the underlying cause, which may be very
diﬃcult to ever determine, a change in strategy must be em-
ployed if we are to change our results. The paradigm shift
from the use of cytotoxic agents to molecularly targeted
agents may be a source of positive change. The theory of
tumor stem cells explaining tumor behavior is an example
of potential fundamental changes in the way we understand
these tumors, which lead to fundamental changes in treat-
ment. Using the gains in the treatment of other condi-
tions that gain high level industry attention (e.g., RANK-L
inhibitors for skeletally related events in metastatic disease
and in osteoporosis) would be another potential area for
improvement. Increased media attention in the form of news
outlets, publications, or even entertainment forums would
direct attention and money to the cause. Empowering aca-
demic centers to research, develop, and even market them-
selves would bring competition into the chemotherapy mar-
ketplace and focus on outcome measures and potentials for
long-term economic gain in the form of cure that short-
sighted companies may not currently see. Increased regula-
tion regarding the use of human subjects in research may be
an issue, but the unfortunate, but real number of patients
withmetastasesmayserveasapoolforsuchstudies,andthus
would be the ﬁrst to beneﬁt.
5. Conclusions
Our study conﬁrms suspicions about the stagnation of
progress in systemic osteosarcoma management in recent
decades. Limb salvage rates have continued to improve sig-
niﬁcantly throughout the modern era to the present day;
however, after tremendous improvement in the 1970’s, sur-
vival measures have failed to demonstrate any further in-
creased since the 1980’s. After 30 years of lack of progress, we
should reevaluate our treatment paradigms and think along
diﬀerent lines, especially in regard to the current players be-
hind drug and medical technology development as well as
ourownattitudestowarddiseasetreatmentandoutcomeswe
deem appropriate.
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